Thomas pike to join labcorp as president and chief executive officer of its drug development clinical development business unit

Burlington, n.c.--( business wire )--labcorp (nyse: lh), a leading global life sciences company, today announced that thomas (tom) pike will join labcorp as president and chief executive officer of its drug development clinical development business unit on jan. 9, 2023. until the planned spin-off of the clinical development business, which is expected to occur in mid-2023, mr. pike will report to labcorp's chairman and ceo adam schechter. at the time of the spin-off, mr. pike will serve as the chief executive officer and chairman of the board of the independent, publicly listed company. in the coming months, labcorp will announce the board of directors of the new company, including its lead independent director.
LH Ratings Summary
LH Quant Ranking